Abstract 833P
Background
In this study, we summarize the chemokines that are involved in malignant HTLV-1 associated disease, adult T cell leukemia/lymphoma (ATLL) progression. The interaction of virus and host were evaluated in chemokine level.
Methods
The expression of CCR6, CXCR-3, the HTLV-1 proviral load (PVL), HTLV-1-Tax, and HBZ were assessed in 12 asymptomatic HTLV-1carriers (ACs), 12 healthy controls (HCs) and 12 ATLL patients. We applied quantitative real-time PCR (qRT-PCR) and TaqMan method.
Results
As per results, the level of CXCR3 gene expression in ATLL patients compared to HTLV-1 virus carriers and healthy people showed a significant difference (P=0.00 and P=0.008). Also, the mean expression of CCR6 genes in ATLL patients compared to HTLV-1 virus carriers had a significant difference of P=0.04, but in the ATLL group there was no significant difference compare to the healthy group.
Conclusions
Our study results illustrate that the expression of chemokine receptors is directly related to the course and stages of the disease as well as the prognosis of the disease. In carriers, compared to healthy individuals, we still have a higher level of expression of chemokine. In addition with the progression of the conflict and the progression to malignancy and involvement of T lymphocytes (the producer of these chemokines) as shown in our study, we can conclude that with decreased levels of these chemokine receptors can lead to malignancy with a poor prognosis. Our findings confirms previous studies that Tax protein may not be expressed in ATLL patients. Additionally an oncoprotein may involve in inducing malignancy, but in the absence of Tax, HTLV-1-HBZ protein implicated in the maintenance of mechanism of the virus to escape from the host cell immune system. We also found an increase in virus load as HTLV-1 carriers move toward. So these chemokines could be suggested as influential targets for the prognosis and proper therapy of ATLL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18